美股异动丨强生(JNJ)涨超3% 因阿片类药物案件被判赔5.72亿美元 罚金远低于市场预期
格隆汇8月27日丨强生(JNJ)现涨3.26%,报131.965美元,暂成交7.48亿美元,最新总市值为3482.77亿美元。昨日,强生阿片类止痛药诉讼告终,强生被裁定需支付5.72亿美元的赔偿金。不过,这远远低于部分投资者在案件一审期间形成的预期。此前投资者预期,强生在这起案件中将面临高达20亿美元的损失。而且,俄克拉荷马州检方的要求是,强生需支付高达175亿美元的罚款,用于补偿解决阿片类药物成瘾和用药过量问题所需的税款。富国银行分析师David Maris在一份报告中指出,深陷阿片类药物诉讼中的制药企业还有许多,强生诉讼中的裁决将有可能作为基准,这对其他阿片类药物而言是一则利好。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.